Monte Rosa Therapeutics, Inc. GLUE Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $42.95M-73.1% | $123.67M+63.5% | $181.54M+1,112% | $177.99M+2,991% | $159.49M+14,889% | ||
| $153.38M+21.0% | $141.5M+16.4% | $138.39M+26.0% | $129.33M+17.0% | $126.73M+13.6% | ||
| $37.85M+8.5% | $36.38M+3.4% | $34.64M+1.5% | $33.7M-2.8% | $34.89M+4.1% | ||
| $191.23M+18.3% | $177.88M+13.5% | $173.03M+20.2% | $163.03M+12.3% | $161.62M+11.4% | ||
| $191.23M+18.3% | $177.88M+13.5% | $173.03M+20.2% | $163.03M+12.3% | $161.62M+11.4% | ||
| -$148.28M— | -$54.21M— | —— | —— | —— | ||
| -345.2%— | -43.8%— | —— | —— | —— | ||
| $15.09M+30.5% | $12.94M+22.5% | $11.85M+14.6% | $11.99M+24.0% | $11.56M+23.8% | ||
| $16.4M+41.5% | $14.49M+31.9% | $13.44M+34.8% | $13.47M+41.9% | $11.59M+26.8% | ||
| $0-100% | $59K— | $59K— | $59K— | $59K+146% | ||
| -$131.88M— | -$39.72M— | —— | —— | —— | ||
| -$1.93M-158% | -$1.16M-145% | $1.01M+148% | $4.26M+743% | $3.31M+647% | ||
| -$129.99M— | -$38.6M— | —— | —— | —— | ||
| -302.6%— | -31.2%— | —— | —— | —— | ||
| -$1.48— | -$0.46— | —— | —— | —— | ||
| 347.5M+12.1% | 330.6M+15.1% | 321.5M+21.4% | 321.1M+38.0% | 310.1M+47.1% | ||
| 347.5M+12.4% | 329.8M+14.8% | 320.6M+21.1% | 320.3M+37.7% | 309.3M+46.7% | ||
| $15.09M+30.5% | $12.94M+22.5% | $11.85M+14.6% | $11.99M+24.0% | $11.56M+23.8% | ||
| -$1.48— | -$0.46— | —— | —— | —— | ||
| -$1.48— | -$0.46— | —— | —— | —— | ||
| -$131.43M— | -$39.1M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $1.35M+4,465% | $1.53M+269% | $1.54M+521% | $1.41M+863% | -$31K+86.2% | ||
| $0-100% | $59K— | $59K— | $59K— | $59K+146% | ||
| —— | —— | —— | —— | —— | ||
| -$148.28M— | -$54.21M— | —— | —— | —— | ||
| -$139.94M— | -$45.85M— | —— | —— | —— | ||
| -$139.94M— | -$45.85M— | —— | —— | —— | ||
| -325.8%— | -37.1%— | —— | —— | —— | ||
| -$148.28M— | -$54.21M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s revenue?
- Monte Rosa Therapeutics, Inc. (GLUE) generated $43.0M in revenue over the trailing twelve months, down 73.1% year over year.
- Is Monte Rosa Therapeutics, Inc. profitable?
- Monte Rosa Therapeutics, Inc. is not currently profitable: it reported a net loss of $130.0M over the trailing twelve months, a -302.6% net margin.
- What is Monte Rosa Therapeutics, Inc.'s earnings per share?
- Monte Rosa Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.48.
- Where does Monte Rosa Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Monte Rosa Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
